Individualized Medicine - Implementation of Pharmacogenetic Diagnostics in Antidepressant Drug Treatment of Major Depressive Disorders

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 3, 2003, Pages

  Kirchheiner, J ^a   Bertilsson, L ^b   Bruus, H ^c   Wolff, A ^c   Roots, I ^a   Bauer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Antidepressants; Cytochrome p450 enzyme; Individualized medicine; Lab on a chip; Major depressive disorder; Pharmacogenetics; Pharmacokinetics

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; DRUG METABOLIZING ENZYME; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

AGE; CARDIOTOXICITY; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; GENDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HALF LIFE TIME; HEART ARRHYTHMIA; HEREDITY; HUMAN; KIDNEY FUNCTION; LIVER; MAJOR DEPRESSION; NEUROTRANSMISSION; PHARMACOGENETICS; PRIORITY JOURNAL; TREATMENT FAILURE; WEIGHT;

EID: 0346639205     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (110)

1. Wittchen H. Epidemiology of affective disorders, in H. Helmchen, F. Henn, H. Lauter and N. Sartorius. Contemporary Psychiatry Springer, Heidelberg: 231-241
2. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 1000-6
3. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5-43
4. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003; 64 Suppl 1: 5-12
5. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49
6. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-22
7. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Brockmöller J. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92
8. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-28
9. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673-7
10. Bertilsson L, Åberg Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15: 388-90
11. Baumann P, Jonzier Perey M, Koeb L, Küpfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1: 102-12
12. Mellström B, Bertilsson L, Lou YC, Säwe J, Sjöqvist F. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1983; 34: 516-20
13. Mellström B, Säwe J, Bertilsson L, Sjöqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986; 39: 369-71
14. Balant Gorgia AE, Schulz P, Dayer P, Balant L, Kubli A, Gertsch C, Garrone G. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 1982; 232: 215-22
15. DUA G. Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152-165
16. Nielsen KK, Brøsen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur J Clin Pharmacol 1992; 43: 405-11
17. Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518-27
18. Steiner E, Alvan G, Garle M, Maguire JH, Lind M, Nilson SO, Tomson T, McClanahan JS, Sjoqvist F. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin. Clin Pharmacol Ther 1987; 42: 326-33
19. Spina E, Steiner E, Ericsson O, Sjöqvist F. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1987; 41: 314-9
20. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986; 40: 543-9
21. Spina E, Gitto C, Avenoso A, Campo GM, Caputi AP, Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395-8
22. Brøsen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679-84
23. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology Berl 1996; 123: 315-9
24. Dalén P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-52
25. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189-93
26. Kirchheiner J, Meineke I, Müller C, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571-80
27. Kirchheiner J, Müller G, Meineke I, Wernecke K, Roots I, Brockmöller J. Effects of polymorphisms in CYP2D6, CYP2C9 and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-66
28. Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K, Jonzier Perey M, Cochard N, Baumann P. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-14
29. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001-6
30. Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widen J, Bertilsson L. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327-35
31. Spigset O, Granberg K, Hagg S, Norström A, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997; 52: 129-33
32. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183-90
33. Spigset O, Granberg K, Hagg S, Söderström E, Dahlqvist R. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257-63
34. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330-4
35. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992; 31: 997-1000
36. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-95
37. Pollock BG, Sweet RA, Kirshner M, Reynolds CF, 3rd. Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 1996; 18: 581-5
38. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger U, Mürdter T, Roots I, Brockmöller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13: 616-26
39. Gabris G, Baumann P, Janzier-perey M, P B, Woggon B, Küpfer A. N-methylation of maprotiline in debrisoquine/ mephenytoin-phenotyped depressive patients. Biochemical Pharmacology 1985; 34: 409-410
40. Firkusny L, Gleiter CH. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994; 37: 383-8
41. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28: 1222-30
42. Barbhaiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 1996; 42: 573-81
43. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7 Suppl 1: S23-35; discussion S71-3
44. Schoerlin MP, Blouin RA, Pfefen JP, Guentert TW. Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr Scand Suppl 1990; 360: 98-100
45. Härtter S, Dingemanse J, Baier D, Ziegler C, Hiemke C. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996; 6: 225-30
46. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670-7
47. Mihara K, Otani K, Suzuki A, Yasui N, Nakano H, Meng X, Ohkubo T, Nagasaki T, Kaneko S, Tsuchida S, Sugawara K, Gonzalez FJ. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology Berl 1997; 133: 95-8
48. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-56
49. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1999; 47: 450-3
50. Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-8
51. Lessard E, Yessine M, Hamelin B, O'Hara G, LeBlanc J, Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435-443
52. Shimoda K, Someya T, Yokono A, Morita S, Hirokane G, Takahashi S, Okawa M. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol 2002; 22: 371-8
53. Jiang ZP, Shu Y, Chen XP, Huang SL, Zhu RH, Wang W, He N, Zhou HH. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J Clin Pharmacol 2002; 58: 109-13
54. Yokono A, Morita S, Someya T, Hirokane G, Okawa M, Shimoda K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J Clin Psychopharmacol 2001; 21: 549-55
55. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49: 18-23
56. Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, Ishizaki T, Kubota T. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 1997; 51: 253-7
57. Koyama E, Tanaka T, Chiba K, Kawakatsu S, Morinobu S, Totsuka S, Ishizaki T. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996; 16: 286-93
58. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42-7
59. Sindrup SH, Brøsen K, Hansen MG, Aaes Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 15: 11-7
60. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8
61. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63
62. Brockmöller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1: 125-51
63. Kirchheiner J, Bauer S, Meineke I, Rohde W, Prang V, Meisel C, Roots I, Brockmöller J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101-109
64. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmader K, Härtter S, Hermann E, Kuss HJ, Laux G, Oehl W, Rao ML, Rollmann N, Weigmann H, Weber-Labonte M, Hiemke C. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 2003; 36: 98-104
65. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31
66. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-4
67. Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ. Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology (Berl) 2000; 150: 120-2
68. Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R. Treatment-resistance to clozapine in association with ultrarapid CYP1 A2 activity and the C-〉 A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001; 21: 603-7
69. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leibach FH. Initial conditions of serotonin transporter kinetics and genotype: influence on SSR1 treatment trial outcome. Biol Psychiatry 2002; 51: 723-32
70. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-9
71. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-11
72. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323-30
73. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-90
74. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-7
75. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, di Bella D, Smeraldi E. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156: 1450-2
76. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, Rupprecht R, Bondy B. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119-22
77. Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002; 46: 136-40
78. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-92
79. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001; 11: 375-80
80. Jonsson EG, Goldman D, Spurlock G, Gustavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci 1997; 247: 297-302
81. Gorman J, Sullivan G. Noradrenergic approaches to antidepressant therapy. J Clin Psychiatry 2000; 61 Suppl 1: 13-6
82. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S, Rupprecht R, Bondy B. Possible influence of the insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001; 6: 258-9
83. Hong CJ, Wang YC, Tsai SJ. Association study of angiotensin 1-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 2002; 109: 1209-14
84. Zill P, Baghai TC, Zwanzger P, Schule C, Minov C, Riedel M, Neumeier K, Rupprecht R, Bondy B. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000; 11: 1893-7
85. Naber CK, Musing J, Wolfhard U, Erbel R, Siffert W. Interaction of the ACE D allele and the GNB3 825T allele in myocardial-infarction. Hypertension 2000; 36: 986-9
86. Bondy B, Baghai TC, Zill P, Bottlender R, Jaeger M, Minov C, Schule C, Zwanzger P, Rupprecht R, Engel RR. Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry 2002; 7: 1120-6
87. Verpoorte E. Microfluidic chips for clinical and forensic analysis. Electrophoresis 2002; 23: 677-712
88. Perch-Nielsen IR, Poulsen CR, El-Ali J, Bang DD, Wolff A. Removal of PCR inhibitors using dielectrophoresis as sample preparation in a microfabricated system. In preparation, 2003
89. Poulsen CR, El-Ali J, Perch-Nielsen IR, Bang DD, Wolff A. Detection of a putative virulence cadF gene of Campylobacter jejuni isolates from different sources using a microfabricated PCR chip. In preparation, 2003
90. Tian HJ, Huhmer AFR, Landers JP. Evaluation of silica resins for direct and efficient extraction of DNA from complex biological matrices in a miniaturized format. Analytical Biochemistry 2000; 283: 175-191
91. Wilding P, Shoffner MA, Kricka LJ. Pcr in a Silicon Microstructure. Clinical Chemistry 1994; 40: 1815-1818
92. Kopp MU, de Mello AJ, Manz A. Chemical amplification: Continuous-flow PCR on a chip. Science 1998; 280: 1046-1048
93. Northrup MA, Benett B, Hadley D, Landre P, Lehew S, Richards J, Stratton P. A miniature analytical instrument for nucleic acids based on micromachined silicon reaction chambers. Analytical Chemistry 1998; 70: 918-922
94. Mello AJd. DNA amplification: does 'small' really mean 'efficient'? Lab on a Chip 2002; 1: 24N-29N
95. Pastinen T, Kurg A, Metspalu A, Peltonen L, Syvänen AC. Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays. Genome Res 1997; 7: 606-14
96. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, Nystrom F, Lind L, Syvanen AC. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13: 7-17
97. Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 1987; 42: 278-82
98. Bergmann TK, Bathum L, Brøsen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol 2001; 57: 123-7
99. Suzuki A, Otani K, Mihara K, Yasui N, Kaneko S, Inoue Y, Hayashi K. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415-8
100. Yue QY, Zhong ZH, Tybring G, Dalén P, Dahl ML, Bertilsson L, Sjöqvist F. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64: 384-90
101. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 2000; 20: 141-9
102. Fjordside , Jeppesen U, Eap CB, Powell K, Baumann P, Brøsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 1999; 9: 55-60
103. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512-21
104. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-87
105. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997; 17: 467-71
106. Dahl ML, Tybring G, Elwin CE, Aim C, Andreasson K, Gyllenpalm M, Bertilsson L. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin Pharmacol Ther 1994; 56: 176-83
107. Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998; 20: 7-13
108. Dahl ML, Voortman G, Aim C, Elwin CE, Delbressine L, Vos R, Bogaards JJP, Bertilsson L. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997; 13: 37-46
109. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003; 13: 39-47
110. Kirchheiner J, Nickchen K, Bauer M, Licinio J, Wong M-L, Roots I, Brockmöller J. Therapeutic implications from pharmacoenetics in antidepressant and antipsychotic drug therapy. Mol Psychiatry, 2004 (in press)